Utah’s Control Medical Technology Gets FDA Clearance for New Mechanical Thrombectomy Platform

May 8, 2020

Control Medical Technology announced on May 7 that the FDA cleared the company’s Control 7 – 11F Mechanical Thrombectomy platform to remove blood clots from peripheral vessels. The device provides clinicians with a more cost-effective tool to remove blood clots. 

“This FDA clearance quadruples our product offering and improves our ability to help patients,” said Shawn Fojtik, President of Control Medical Technology in Park City, Utah. 

“This new device will help save lives,” said Kelvyn Cullimore, president and CEO of BioUtah. “With Shawn’s leadership, I’m confident that Control Medical Technology will continue to deliver innovative technologies for use in peripheral, coronary, and neurovascular procedures.” 

Blood clot removal (thrombectomy) is a common procedure. Coronary thrombectomy is associated with acute myocardial infarction (AMI), neurovascular thrombectomy is associated with acute ischemic stroke, and peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD). Peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD).